Expert insights on antibodies, immunoassay development, and diagnostic reagents from Sekbio's technical team
With self-certification over for most IVDs, notified bodies now review the antibody data inside your technical file. A supplier documentation checklist for IVDR, plus lessons from AMH and CHI3L1 registration projects.
A recap of Sekbio's Shenzhen exhibition: small molecule hapten derivatives, custom synthesis services, and the CDMO one-stop solution drew broad interest and consistently positive feedback from visitors.
HA vs NP targeting, cross-clade epitope coverage for 2.3.4.4b, cattle-strain validation, and LFA/CLIA format fit for H5N1 antibody pair selection ahead of migratory bird season.
Bristol Myers Squibb discontinued the CD33-targeting degrader-antibody conjugate ORM-6151 after a Phase 1 data review — the deal breakdown, the ORM-5029 precedent, and why antibody backbone characterization is the common thread.
A September 2026 report shows Korea imports 95% of its biomanufacturing raw materials — and why dual-sourcing, not supplier replacement, is the realistic fix for antibody and antigen raw material risk.
Asymmetric sensitivity ranges, PlGF isoform coverage, total sFlt-1 detection, VEGF receptor cross-reactivity, and PROGNOSIS ratio cut-off validation for preeclampsia antibody pair development.
Promoter strength, plasmid copy number, selection markers, and tag placement — the vector-design choices that quietly cap recombinant protein yield before cloning even starts.
Sekbio will exhibit at BrightMD Fair China 2026 (Sep 21-23, Shenzhen World Exhibition & Convention Center) with reliable antibody development services and a one-stop antibody engineering solution for IVD and pharma partners.
From amine-contaminated buffers to epitope masking near the paratope, the seven conjugation errors that quietly ruin PCSK9 antibody-HRP conjugates — with a fix protocol for each.
AI-designed de novo proteins neutralized lethal cobra three-finger toxins at a 1:1 ratio and protected mice. How RFdiffusion built them, how they compare to nanobodies and VHH antibodies, and what it means for recombinant antibody engineering.
Hemolysis, lipemia, the high-dose hook effect, and heterophilic antibodies derail lateral flow assay development. The interference pitfalls that fail registration studies, and how to design them out.
Sekbio exhibits at CPHI & PMEC Shenzhen 2026 (September 16–18, SZCEC). Book a booth meeting or a visit to our Shenzhen facility to discuss recombinant antibody expression under an activity-first payment model and hapten synthesis with one-stop CDMO.
Pure-algorithm AI antibody design is cooling off as pharma and CRO buyers demand proof, not predictions. Why self-built robotic wet-lab automation — and fast expression turnaround — has become the real competitive moat in AI-driven antibody discovery.
Under EU IVDR and tighter US review, multinational IVD makers are stripping animal-source ascites hybridoma material out of their assays in favor of sequence-traceable recombinant monoclonals. Why the sequence becomes the specification, and how to plan a hybridoma-to-recombinant conversion for cardiac and inflammation markers.
Light/heavy chain mispairing and rising aggregate levels in transient CHO and HEK293 runs are one linked problem. A five-step lab fix: rebalance the chain plasmid ratio, correct codon usage and signal peptides, tune the culture, screen purification buffers, and confirm with SEC and CE-SDS.
Nirsevimab, clesrovimab, and a dense run of RSV prevention antibody approvals all target one metastable viral protein — the fusion F glycoprotein. Why prefusion-F conformational epitopes are hard to raise antibodies against, and how it connects to respiratory multiplex testing.
Chinese IVD firms are pushing p-tau217 and NfL chemiluminescence assays through registration testing for Alzheimer's blood screening — and the femtomolar analytical challenge of separating specific signal from plasma background noise is where reagent quality decides the outcome.
WuXi XDC's H1 2026 interim results show over 3,100 bioconjugate molecules explored as ADC evolves into AOC, DAC, APC, and bispecific formats — and what the shift demands from conjugation-ready antibody engineering.
Sekbio's Jack Sun presented at Diagmand 2026 in Suzhou, sharing the company's CDMO one-stop model for turning new IVD targets into manufacturable products, plus the AI-assisted chemical synthesis platform behind recent VB12 and progesterone hapten breakthroughs.
Moderna and Merck's intismeran autogene became the first individualized neoantigen therapy to post positive Phase 3 data. Here's how the biopsy-to-dose manufacturing pipeline works, who else is racing to build one, and what it means for the immunoassay and biomarker reagent supply chain behind it.
NMPA's approval of iza-bren (BL-B01D1) puts the spotlight on chain mispairing — the combinatorial assembly problem that makes bispecific antibodies harder to manufacture than conventional monoclonal antibodies, and how engineered formats and expression platforms solve it.
Why Protein A/G fails on IgM, the buffer strategy mistakes that tank recovery, and the pentamer-level validation step most labs skip — a practical troubleshooting guide for IVD developers.
HE4 normal range by menopausal status, how the HE4 blood test works, what elevated levels mean, and why HE4 is paired with CA125 in ovarian cancer risk assessment (ROMA score).
Antibody ELISA needs E protein; antigen sandwich tests need NS1. A practical antigen-selection guide covering detection windows, serotyping, and Zika cross-reactivity for dengue IVD developers.
Real customer-run cassette photos show faint-but-valid positive T lines — and why the antibody pair behind Sekbio's bovine PAG rapid test is engineered specifically to keep them readable.
How Sekbio engineered a recombinant anti-testosterone antibody in CHO cells — hapten conjugation, DHT cross-reactivity screening, and the diagnostic challenges of a small-molecule biomarker.
How Sekbio engineered a recombinant anti-estradiol antibody in CHO cells — hapten conjugation, cross-reactivity screening, and the diagnostic challenges of a small-molecule biomarker.
A pH x coating-ratio screening case study showing up to 180-fold S/N sensitivity gains over a mainstream commercial derivative.
Why a correctly-sequenced, high-purity E. coli antigen can still fail immunoreactivity — refold verification, epitope loss, and batch drift explained.
The recurring CHO cell mistakes — clone selection, glycosylation drift, HCP/HCD carryover, and feed strategy — that quietly erode antibody titer and quality.
Common pitfalls in vitamin B12 assay development, why native cobalamin can't be used directly, and the criteria that separate a workable vitamin B12 derivative from a problematic one.
Codon bias, wrong strain, uncontrolled induction, and unrecognized toxicity sink more E. coli expression projects than difficult targets do — here's how to diagnose and fix each one.
Poor conjugation yield usually traces back to lysine, cysteine, or tyrosine residues you never checked for exposure and reactivity — here's what to verify before your next crosslinking reaction.
What CA125, AFP, and CEA each actually surveil, why they're not a unified cancer score, and how to interpret the far more common discordant panel result.
Why progesterone assays require competitive format, how to validate against 17-hydroxyprogesterone cross-reactivity, and matrix effects that matter when porting CLIA reagents to a whole blood LFA cartridge.
A monitoring schedule for TRT — trough timing by delivery route, target treatment levels, total vs. free testosterone, and the hematocrit/PSA safety labs a follow-up panel should cover.
Onset, peak, and clinical role compared across myoglobin, cTnI, and NT-proBNP — why injury markers and strain markers answer different questions, and how 0/1h rule-out algorithms use these kinetics in practice.
A developer's guide to AMH antibody pair selection — proAMH vs. cleaved form specificity, epitope pairing, cross-reactivity screening against inhibin B, and dynamic range validation from DOR through PCOS-range concentrations.
Onset, peak, and half-life compared across CRP, PCT, and IL-6, plus the two clinical scenarios — early presentation and the CRP gray zone — where combination biomarker testing genuinely improves diagnostic accuracy.
A four-step PCT algorithm for antibiotic initiation and discontinuation in sepsis — cutoff thresholds, serial monitoring intervals, and evidence from ProHOSP, PRORATA, SAPS, and ProACT trials.
The most common surfactant selection mistakes in lateral flow assay development — HLB and charge compatibility, critical micelle concentration, conjugate stability, and matrix-specific formulation errors.
GIST and Chonnam National University researchers used Sekbio's W37M/W36M influenza A antibody pair to build TELFIA, an ultrasensitive rapid test validated at 96.8% sensitivity against RT-PCR.
The most common — and costly — mistakes IVD developers make when screening antibodies, starting with mistaking research-grade antibodies for IVD-grade reagents, plus a practical screening checklist.
Normal progesterone levels by menstrual cycle phase, pregnancy trimester and menopause, what causes low or high progesterone, progesterone in early pregnancy, and how progesterone and estrogen work together.
A complete guide to AMH — normal anti-Müllerian hormone levels by age, what low and high AMH mean for fertility and PCOS, how the AMH blood test works, and the real relationship between AMH and IVF success rates.
A comprehensive reference guide to testosterone — normal ranges by age and sex, symptoms of low and high testosterone, how free vs. total testosterone are measured, and what the numbers mean clinically. Includes reference tables for men and women across life stages.
Everything clinicians and patients need to know about prostate-specific antigen (PSA) screening — age-stratified normal ranges, what elevated PSA means, current screening guidelines (ACS / USPSTF), and how free PSA ratio refines interpretation.
A definitive guide to PCSK9 — the mechanism behind LDL receptor recycling, how evolocumab and alirocumab block it, a complete inhibitors drug list with dosing, and a head-to-head comparison with statins for cardiovascular risk reduction.
What is D-dimer and why does it matter? This guide covers the standard and age-adjusted normal ranges, the most common causes of elevated D-dimer, quantitative vs. qualitative assay formats, and its role in ruling out DVT and pulmonary embolism.
CRP and hs-CRP explained — normal ranges, what high CRP means across different conditions (rheumatoid arthritis, cardiac risk, neonatal infection, appendicitis), the difference between standard and high-sensitivity CRP, and evidence-based guidance on when to order each test.
From VH/VL sequencing via mRNA RT-PCR or LC-MS/MS de novo to CHO/HEK293 expression and functional equivalence validation — a step-by-step technical guide for IVD developers looking to replace discontinued hybridoma-sourced antibodies with recombinant equivalents.
A decade-by-decade analysis of ADC patent strategy — antibody, linker, and toxin claims, Fc engineering IP, freedom-to-operate considerations, and the landmark Seagen v. Daiichi Sankyo ruling.
Root causes of lot-to-lot variability, measurable QC parameters (CV, SEC-HPLC, binding activity), regulatory requirements, and supplier qualification criteria for IVD-grade antibodies.
Antibody pair selection, coating and blocking optimization, standard curve design, and performance validation — including LOD calculation, hook effect prevention, and spike recovery protocols.
CHI3L1/YKL-40 biology, clinical significance in liver fibrosis, COPD, and cancer progression, plus practical ELISA and rapid test assay development guidance for IVD professionals.
CDR affinity maturation, framework stability engineering, site-specific conjugation design, and deamidation/oxidation hotspot removal for ELISA, CLIA, and lateral flow platforms.
Error-prone PCR, gene shuffling, structure-guided mutagenesis, and display screening — a senior antibody engineer's practical guide to directed evolution for IVD antibody optimization.
Sekbio exhibited at Medica 2025 in Düsseldorf, connecting with IVD partners from 30+ countries. A recap of the world's largest medical trade fair — our antibody panels, CHO expression services, and new conversations that turned into collaborations.
Wrong adsorption pH, skipping the flocculation test, bad antibody-to-gold ratios, insufficient blocking, and mismatched particle size — the five conjugation errors that cause most LFA failures, with diagnostic checks and fix protocols for each.
A practical decision guide comparing CHO and HEK293 for IVD antibody production — yield targets, glycosylation differences, regulatory documentation requirements, and the three pitfalls that cost teams months when switching expression systems mid-development.
A practical Q&A covering checkerboard ELISA screening, KD affinity targets, colloidal gold vs. fluorescent microsphere conjugation requirements, recombinant vs. hybridoma antibody sourcing, and hook effect troubleshooting — for IVD R&D engineers building POCT strips.
A deep dive into the structural biology and antiviral mechanism of MxA — why its interferon-exclusive induction logic makes it the most diagnostically specific blood biomarker for viral infection, and what IVD developers need to know about building CLIA and LFA assays around it.
China's MOST has opened the 2026 Batch 2 Intergovernmental S&T Cooperation program — funding joint R&D between Chinese and international partners. Learn which directions suit IVD and antibody companies, how to find a partner, and how to apply before the June 25 deadline.
The Shenzhen Chapter of SYSU Alumni Association toured Sekbio's ISO 13485-certified R&D labs, cleanrooms, and production QC. A constructive dialogue on IVD industry challenges, academic partnerships, and investment opportunities.
A comprehensive review of Ebola virus nucleoprotein — its molecular structure, three forms in patient blood (virion, extracellular vesicles, free from lysis), and why NP outperforms VP40 and GP as a rapid diagnostic test target.
Matching capture and detection antibodies for sandwich immunoassays: key criteria including epitope mapping, affinity thresholds, and practical optimization tips for IVD developers.
From antigen coating optimization to assay validation — a step-by-step guide for diagnostic assay developers building ELISAs for routine IVD workflows.
Why CHO cells dominate recombinant protein production for diagnostics. A technical deep-dive into glycosylation, scalability, and what it means for your IVD assay antigen performance.
Mammalian vs. insect vs. bacterial: which expression platform is right for your IVD assay? A technical comparison covering glycosylation, yield, cost, and regulatory considerations.
A landmark 2026 benchmark from Stanford and Harvard evaluates LLM agents on 100 real biomedical tasks. Key finding: agent architecture matters more than model choice — all frontier models fail at method selection and biological reasoning.
AlphaDynamics simulates protein conformational dynamics 21,000× faster than classical MD on a single consumer GPU, using phase-oscillator networks and torus-native geometry — a breakthrough in computational biophysics.
WHO confirmed an Andes hantavirus cluster aboard the MS Hondius in May 2026. This technical guide covers hantavirus biology, the IgM/IgG diagnostic window, and a step-by-step strategy for developing serological assays.
HRP2 gene deletions in P. falciparum are rendering standard malaria RDTs blind worldwide. Discover how GAPDH and DHFR-TS — essential, undeletable enzymes — are leading the race toward evolution-proof diagnostics.
Deep dive into antigenic variation: from Trypanosoma brucei's coat switching to HIV's predictable escape pathways. Explore the molecular disguise mechanisms pathogens use to evade the immune system and how modern diagnostics catch them.
Comprehensive guide to Vitamin D detection using ELISA for routine IVD workflows. Learn about assay optimization, performance parameters, and troubleshooting tips for accurate 25-hydroxyvitamin D measurement.
Explore the development of rapid test kits for Nipah virus detection, including assay design challenges, sensitivity requirements, and implementation strategies for outbreak control.
Detailed overview of Cholera O1 antibodies, their applications in diagnostic assay development, and best practices for ensuring specificity and sensitivity in cholera detection systems.
Learn how Sekbio helped a diagnostic manufacturer achieve sub-pg/mL sensitivity for cardiac troponin I detection through advanced antibody engineering and assay optimization techniques.
Introducing our new IL-6 antibody pair with enhanced sensitivity for detecting cytokine levels in sepsis and COVID-19 patients. Performance data and application examples included.
Comprehensive guide to selecting optimal antibody pairs for sandwich immunoassays, covering epitope mapping, affinity considerations, and validation protocols for reliable assay performance.